Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17066970 | 0.84 | PTGS2 (0.60) | DRD1PTGS2PTGS1ATR | |
| SCHEMBL20371519 | 0.82 | CA2 (0.56) | DRD1PTGS2PTGS1CA12CA1 | |
| SCHEMBL15730108 | 0.82 | DRD1 (0.54) | DRD1SMN1; SMN2NPC1RAB9APTGS2 | |
| SCHEMBL23501963 | 0.80 | ALDH1A1 (0.54) | SMN1; SMN2GAALMNAHTTIKBKB | |
| SCHEMBL18853895 | 0.79 | ALDH1A1 (0.53) | SMN1; SMN2PTGS2PTGS1CA1CA2 | |
| SCHEMBL25972916 | 0.79 | DRD1 (0.46) | DRD1SMN1; SMN2CA1CA2LIMK2 | |
| SCHEMBL18853896 | 0.78 | DRD1 (0.50) | DRD1SMN1; SMN2NPC1RAB9APTGS2 | |
| SCHEMBL20371667 | 0.77 | IKBKB (0.48) | SMN1; SMN2NPC1RAB9AGAALMNA | |
| SCHEMBL15408443 | 0.75 | IKBKB (0.50) | DRD1SMN1; SMN2NPC1RAB9APTGS2 | |
| SCHEMBL20371609 | 0.75 | SYK (0.46) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | DRD1 3722/4885SMN1; SMN2 3500/4885NPC1 2/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | DRD1 3722/4885SMN1; SMN2 3500/4885NPC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.